Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Alzheimer's
Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation
By
LabPulse.com staff writers
The Alzheimer's blood test developed through a collaboration between Roche and Lilly has been granted a breakthrough device designation by the U.S. Food and Drug Administration (FDA).
April 11, 2024
FDA updates draft guidance for Alzheimer's drug development biomarkers
By
LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.
March 14, 2024
Eisai invests $15M in C2N to increase Alzheimer's test access
By
LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
Alzheimer’s study results show correlation between blood-based biomarkers and amyloid plaques
By
LabPulse.com staff writers
The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).
March 1, 2024
NHS lacks capacity for Alzheimer’s diagnostics, warn experts
By
Matt Limb
Many thousands of patients in the U.K. could miss out on new treatments for Alzheimer’s disease because its National Health Service (NHS) lacks capacity for diagnostic tests, warn experts.
February 14, 2024
Blood test for Alzheimer’s shows high accuracy in study
By
Matt Limb
Scientists have hailed study results showing the high accuracy of a blood test that “could revolutionize” diagnosis of Alzheimer’s disease.
January 31, 2024
Study: Focused ultrasound improves Alzheimer’s drug delivery
By
Matt Limb
Alzheimer’s disease researchers have reported promising results from using aducanumab infusions combined with focused ultrasound to reduce levels of cerebral amyloid-beta (Aβ) plaques.
January 17, 2024
AI-driven method developed to identify therapeutic targets
By
Matt Limb
Researchers have developed a method of identifying therapeutic targets for human diseases associated with protein phase separation that they say could be used to discover targets for Alzheimer’s and other neurogenerative diseases.
October 17, 2023
Protein panel improves Alzheimer’s diagnosis, predictions of disease progression
By
Nick Paul Taylor
Quantifying certain proteins in cerebrospinal fluid could improve the diagnosis of Alzheimer's disease and prediction of disease progression, according to a paper in Science Translational Medicine.
October 3, 2023
Alzheimer’s drug approval poised to reshape APOE testing market
By
Nick Paul Taylor
The U.S. Food and Drug Administration (FDA) approval of Biogen and Eisai’s Alzheimer’s disease drug Leqembi is likely to drive changes in the APOE testing market, according to an article in GenomeWeb.
September 25, 2023
Experts raise concerns about Quest Diagnostics’ consumer-initiated Alzheimer’s test
By
Nick Paul Taylor
Experts have raised concerns about Quest Diagnostics’ $399 consumer-initiated Alzheimer’s disease test, telling 360Dx that it is unclear whether the product is accurate enough to support its use.
September 15, 2023
C2N Diagnostics rolls out second-generation Alzheimer's disease biomarker test
By
Matt Limb
C₂N Diagnostics has unveiled its “next generation” blood biomarker test to evaluate patients with signs and symptoms of Alzheimer’s disease (AD) and other causes of cognitive decline.
August 29, 2023
Page 1 of 8
Next Page